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The evidence-based pharmacological treatment
of paediatric ADHD

THEMATIC SECTION
Attention-Deficit Hyperactivity
Disorder (ADHD)

Brigette S. Vaughan1, John S. March2 and Christopher J. Kratochvil1
1
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University of Nebraska Medical Center, NE, USA
Duke University Medical Center, NE, USA

Abstract
Attention deficit hyperactivity disorder (ADHD) is common in children, adolescents, and adults, with
extensive research establishing it as a valid neurobiological disorder. Without intervention, ADHD can
result in significant impairment throughout the lifespan for the individuals it afflicts. Fortunately, multiple
evidence-based options are available for the treatment of ADHD, including several efficacious
pharmacotherapies. The role of medication, including stimulants as well as non-stimulants, is welldocumented by an extensive body of literature. Although there may be less enthusiasm for behavioural
and other psychosocial interventions as stand-alone treatments for moderate to severe ADHD, they are
recommended as first-line treatment for ADHD management in preschool-aged children, for those
patients with mild symptoms, and as an adjunct to medication in patients with comorbid disorders or
suboptimal responses to pharmacotherapy. When planning treatment for individuals with ADHD, the
potential risks associated with the available interventions must be carefully balanced against the risks of
not treating, or not treating adequately. The treatment plan must also include ongoing re-assessment of the
effectiveness of and the need for continued therapy. Recent practice parameters provide further specific
guidance for the evidence-based assessment and treatment of children and adolescents with ADHD.
Received 30 August 2010 ; Reviewed 28 October 2010 ; Revised 29 November 2010 ; Accepted 13 January 2011 ;
First published online 18 February 2011
Key words : ADHD, attention, hyperactivity, pharmacotherapy.

Introduction
Attention deficit hyperactivity disorder (ADHD) is
a neurobiological disorder, affecting significant numbers of children, adolescents, and adults worldwide.
Research throughout the past century has established
a strong scientific foundation for our current understanding of the aetiology, epidemiology, and treatment of ADHD. The American Medical Association’s
Council on Scientific Affairs in 1998 stated, ‘Overall,
ADHD is one of the best-researched disorders in
medicine, and the overall data on its validity are far
more compelling than for many medical conditions ’
(Goldman et al. 1998). The American Academy of
Child & Adolescent Psychiatry (AACAP), in their
2007 ADHD Practice Parameters concluded, ‘Although scientists and clinicians debate the best way to
Address for correspondence : Dr C. J. Kratochvil, Department
of Psychiatry, 985581 Nebraska Medical Center, Omaha, NE 681985581, USA.
Tel. : (402) 552-6005 Fax : (402) 552-6247
Email : ckratoch@unmc.edu

diagnose and treat ADHD, there is no debate among
competent and well-informed healthcare professionals
that ADHD is a valid neurobiological condition that
causes significant impairment in those whom it afflicts ’
(Pliszka, 2007).
Neuropsychological, neuroimaging, and genetic
studies have demonstrated the biological underpinnings of ADHD. These studies have correlated
deficits in executive functioning, response inhibition,
delay aversion, vigilance, working memory, and
planning with specific regions of the brain (Willcutt
et al. 2005). Structural imaging studies have demonstrated that children with ADHD have significantly
smaller brain volumes, on average, than same-aged
comparison children (Castellanos & Tannock, 2002 ;
Durston et al. 2004 ; Mostofsky et al. 2002), with smaller
cerebellar and total cerebral volumes noted
(Castellanos et al. 2002). In addition, functional imaging has revealed discrete variations in brain activation, specifically in the frontal-striatal cerebellar
circuits (Krain & Castellanos, 2006). Family, twin, and
more recently, genotyping studies provide further
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support for the biological basis of ADHD. There is
considerable evidence that the principal cause of
ADHD is genetic, with an estimated heritability of
76 % (Faraone et al. 2005). Parents of children with
ADHD are 2–8 times more likely to have the disorder
themselves, and the risk is similar for siblings of affected children (Faraone & Biederman, 2000).
ADHD prevalence has been conservatively estimated to occur in 3–7 % of children (APA, 2000), with
other estimates as high as 7–12 % (CDC, 2005 ;
Woodruff et al. 2004). While most commonly diagnosed between ages 7 and 10 yr, symptom presentation and impairment can often be seen in children as
young as age 3 yr (Lavigne et al. 1996). Epidemiological studies have shown that 2–6 % of preschool children meet diagnostic criteria for ADHD (Angold et al.
2000 ; Lavigne et al. 1996). Of those diagnosed with
ADHD as children, 60–85 % continue to meet criteria
for the disorder as adolescents, and as many as 60 %
continue to experience symptoms as adults (Barkley
et al. 1990, 2002 ; Biederman et al. 1996 ; Kessler et al.
2005).
A comprehensive differential diagnosis is essential
for an accurate evaluation. Behaviours which are
characteristic of normal childhood development may
be misinterpreted as ADHD if not considered in an
age-appropriate context. In addition, developmental
disabilities, learning disorders, mental retardation,
and hearing or vision impairments, as well as general
medical problems such as hyperthyroidism, partial
complex seizures, or lead toxicity may mimic ADHD.
Several aspects of the core symptoms of inattention,
hyperactivity, and impulsivity, can also be indicative
of depressive and anxiety disorders, substance abuse,
or paediatric bipolar disorder.
The diagnostic criteria for ADHD require the presence of at least 6/9 inattentive symptoms, and/or 6/9
hyperactive-impulsive symptoms, with onset prior to
age 7 yr. Symptoms must be developmentally inappropriate and result in clinically significant impairment in social, academic, and/or occupational
functioning (APA, 2000). Even preschool children with
ADHD are at high risk for academic, social, behavioural and family dysfunction due to the disorder
(DuPaul et al. 2001), and are more likely to be placed in
specialized educational settings (Lahey et al. 2004 ;
Lahey et al. 1998). These children also have increased
rates of accidents and injuries (Lahey et al. 1998), aggression (Connor et al. 2003), and internalizing symptoms (Cunningham & Boyle, 2002). School-aged
children with ADHD as a group have more difficulties
with peer interactions, academic tasks, and conflicts
with parents than do same-aged peers without

ADHD. In addition to ongoing difficulties common to
younger children, adolescents have elevated rates of
substance use and abuse, motor vehicle accidents,
academic and occupational impairments, teen pregnancy, and sexually transmitted diseases (Barkley,
2006).
Nearly two-thirds of children diagnosed with
ADHD also have at least one co-occurring psychiatric condition. The Multimodal Treatment Study of
Children with ADHD (MTA) consisted of one of the
largest and best characterized ADHD populations to
date (n=579 children aged 7–9.9 yr), and demonstrated that only 31 % of participants had ADHD
alone, while 40 % also met criteria for oppositional
defiant disorder, 38 % for anxiety/mood disorders,
14 % for conduct disorder, and 11 % for tic disorders
(MTA Cooperative Group, 1999).
The National Initiative for Children’s Healthcare
Quality (NICHQ) recommends that children with
ADHD and their families receive individualized
treatment with ongoing support and education
(Bodenheimer et al. 2002a, b). They recommend that an
effective ADHD management plan for children should
generally include parent training, behavioural modification and social-skills training, and school-based interventions. In preschool children, or those with mild
symptoms, the AACAP (Pliszka, 2007) and American
Academy of Pediatrics (AAP, 2001) recommend a trial
of behavioural interventions prior to starting medication. Unfortunately, studies have shown that while
behavioural therapies offer some benefit, they may
have limited effectiveness as a monotherapy for treating moderate to severe ADHD. In the majority of cases,
behavioural interventions may be only one component
of a more extensive treatment plan.
The MTA study randomized participants to intensive behavioural therapy, pharmacotherapy with systematically delivered methylphenidate, a combination
of the two, or standard community care. The pharmacotherapy and combined treatment groups demonstrated significant improvement, and both were
superior to behavioural therapy alone. Interestingly,
however, the combined treatment group’s response
was not significantly better than pharmacotherapy
alone for the treatment of core ADHD symptoms.
Medication, therefore, appears to have the most significant acute impact on the treatment of ADHD (MTA
Cooperative Group, 1999). The addition of behavioural interventions to pharmacotherapy did, however,
increase parent and teacher satisfaction with treatment, improved the child’s interpersonal relationships, and on average, children receiving behavioural
interventions required lower medication doses (MTA

Evidence-based ADHD pharmacotherapy
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Table 1. Treatment recommendations from the AACAP Practice Parameters for the assessment and treatment of ADHD
(Pliszka, 2007)
Treatment

$

$

$

$

The treatment plan for the patient with ADHD should
be well thought out and comprehensive.
Pharmacological treatment should begin with an agent
approved by the FDA for the treatment of ADHD.
If a patient responds robustly to pharmacotherapy,
medication treatment of their ADHD alone may be
sufficient.
If none of the FDA-approved medications result in
satisfactory treatment, the clinician should review the
diagnosis and consider behavioural therapy and/or the
use of medications not approved by the FDA for the
treatment of ADHD.

Cooperative Group, 1999). A later study of children
aged 3–5.5 yr with moderate to severe ADHD, the
Preschool ADHD Treatment Study (PATS), demonstrated limited response to behavioural therapy alone,
resulting in the majority of children warranting the
initiation of pharmacotherapy following treatment
with only behavioural intervention (Greenhill et al.
2006).

Monitoring

$

$

$

$

Table 2. Treatment algorithm for preschool children with
ADHD (Gleason et al. 2007)
General principles

$

$

Practice parameters
The AACAP Practice Parameters for ADHD published
in 2007 combine short- and long-term empirical evidence with expert opinion from paediatric mental
health researchers and clinicians. They offer specific
recommendations (Table 1) for a comprehensive
treatment plan, potentially consisting of pharmacological and behavioural interventions, and that if
pharmacotherapy is indicated, the initial agent selected should be one with Food and Drug Administration
(FDA) approval for ADHD. The AACAP further states
that if the response to an FDA-approved treatment is
robust and normalizes the patient’s functioning,
medication alone may be sufficient (Pliszka, 2007).
In their 2001 clinical practice guideline for treating
ADHD in children, the AAP recommended that the
first intervention for the young child with ADHD be
behavioural (AAP, 2001). The 2007 AACAP (Pliszka,
2007) parameters indicate that behavioural therapy
alone may be appropriate in mild cases of ADHD and
should be considered for young children. Additionally, Gleason and colleagues made specific recommendations regarding treatment algorithms for
pharmacotherapy in preschool-aged children (Table 2)

Patients receiving pharmacotherapy for ADHD should
have their height and weight monitored throughout
treatment.
The patient should be monitored for treatment-emergent
side-effects during pharmacotherapy.
If a patient has a suboptimal response to medication,
comorbid diagnosis, or psychosocial stressors, adjunctive
psychosocial intervention is often beneficial.
Treatment should continue as long as
symptoms remain present and cause
impairment. The need for treatment should
be periodically reassessed.

$

$

$

$

Assessment and diagnosis should be
comprehensive, developmentally appropriate
and contextually sensitive.
An adequate trial of psychotherapy should
precede pharmacotherapy, and should continue
even if medication is used.
Pharmacotherapy should be considered in the
context of the clinical diagnosis and degree of
functional impairment.
Referral of the parent for treatment may
optimize family mental health.
Medication discontinuation trials are
recommended following 6 months of treatment.
The use of additional medication to manage
side effects of medication is discouraged.

Stage 0 : Diagnostic assessment and psychotherapeutic
intervention
Stage 1 : Methylphenidate trial
Stage 2 : Amphetamine trial
Stage 3 : a-adrenergic or atomoxetine trial

(Gleason et al. 2007). Gleason and colleagues went on
to specifically address treatment of preschool-aged
patients with ADHD and referenced the PATS study
when providing guidance for treating young children
with a psychostimulant. The AACAP does note that
subjects in PATS were only randomized to pharmacotherapy if they did not demonstrate significant or
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Table 3. Medications with FDA approval for the treatment of ADHD
Duration of
effect (Daughton
& Kratochvil,
2009)

Trade name

Name

Delivery system

Methylphenidate

Solution
Chewable tablet
Tablet
Sustained
release tablet
Beaded capsule

4h
4h
4h
Up to 8 h

Methylin
Methylin
Ritalin
Ritalin SR

7–8 h

Beaded capsule
OROS capsule
Transdermal patch
Tablet
Beaded capsule
Tablet
Beaded capsule
Tablet

8–9 h
Up to 12 h
12 h
4h
Up to 12 h
6h
10 h
4h

Spansule capsule

10 h

Capsule
Capsule
Tablet

10 h
24 h
8–12 h

Metadate ER,
Methylin ER,
Ritalin LA
Metadate CD
Concerta
Daytrana
Focalin
Focalin XR
Adderall
Adderall XR
Dexedrine,
Dextrostat
Dexedrine
Spansule
Vyvanse
Strattera
Intuniv

Tablet

12 h

Kapvay

d-Methylphenidate
Amphetamine
d-Amphetamine

Lisdexamfetamine
Atomoxetine
Guanfacine
extended-release
Clonidine
extended-release

satisfactory improvement following 10 wk of parent
training (Greenhill et al. 2006).
What is the first-line treatment for ADHD?
The role of pharmacotherapy (Table 3) as a first-line
treatment of ADHD is strongly supported in the
literature (Biederman & Spencer, 2008). The stimulant
medications have decades of efficacy data from hundreds of controlled trials, beginning as early as the
1930s, and were well-established as effective treatments for ADHD by the 1970s. The paediatric safety
and efficacy database on acute and long-term use of
these agents has continued to grow and includes data
not only on school-aged children, but more recently
has expanded into preschool children and adolescents
(AAP, 2001 ; Biederman & Spencer, 2008 ; Brown et al.
2005 ; Greenhill et al. 2002 ; Pliszka et al. 2007). There
has also been a significant increase in data supporting
the utility of non-stimulant agents for ADHD in the
past 10 yr (AAP, 2001 ; Biederman & Spencer, 2008 ;

Brown et al. 2005 ; Greenhill et al. 2002 ; Madaan et al.
2006 ; Pliszka et al. 2007). A meta-analysis of atomoxetine and stimulant studies revealed a robust effect
size for atomoxetine and the stimulants, both of which
are currently approved by the FDA for the treatment
of ADHD. Atomoxetine demonstrated an effect size of
0.62, which would be considered a medium effect size,
compared to 0.91 and 0.95, considered large effect
sizes, for immediate- and extended-release stimulants,
respectively (Faraone, 2003). A more recent FDAapproved agent, the a2 agonist guanfacine XR, demonstrated effect sizes of 0.43–0.86 in two double-blind,
placebo-controlled (DBPC) trials (Biederman et al.
2008b ; Sallee et al. 2009b).
Stimulants
Stimulants have historically been considered a firstline treatment for ADHD, with approximately 75 %
of children responding to the first agent selected,
and 80–90 % eventually responding if two different
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stimulants are tried consecutively (Pliszka, 2003).
Although the MTA study examined the use of immediate-release methylphenidate, extended-release
preparations are now commonly used to improve adherence to the treatment schedule, thus providing less
opportunity for gaps in coverage. A combination of
immediate- and extended-release preparations, selected and titrated according to tolerability and response,
may ultimately be required to optimally manage the
child’s individual pharmacotherapy needs. All stimulant medications currently approved for the treatment
of ADHD are derivatives of either methylphenidate or
amphetamine, both of which act by enhancing the
neurotransmission of dopamine, and to a lesser extent,
norepinephrine (Biederman & Spencer, 2008). DBPC
studies in children, adolescents and adults have demonstrated that 65–75 % of subjects typically respond to
stimulant treatment, compared to 4–30 % of those on
placebo (Greenhill et al. 2002 ; Pliszka, 2007). Recent
research has focused on improving the delivery
mechanisms of the stimulant medications in order to
extend the duration of action. With multiple formulations of these medications (short-, intermediate- and
long-acting) as well as a variety of administration options available (e.g. capsules, sprinkleable capsules,
tablets, chewable tablets, oral solution, transdermal
patches), treatment can be tailored to individual
patient needs.
The MTA study demonstrated the tolerability and
efficacy of t.i.d. immediate-release methylphenidate in
a randomized trial of 579 children aged 7–9.9 yr with
the combined subtype of ADHD. Dose titration was
based on effect as reported by parent and teacher rating scales, and tolerability. Children in the manualized
pharmacotherapy arm of the study had mean final
doses of 32.1¡15.4 mg/d, and those assigned to
manualized pharmacotherapy plus behavioural intervention had mean final doses of 28.9¡13.7 mg/d. The
MTA study allowed children weighing <25 kg to
have methylphenidate doses of up to 35 mg/d, and
allowed doses up to 50 mg/d for children who
weighed more. Average doses in the smaller children
were 0.95¡0.40 mg/d, and 1.13¡0.55 mg/d in those
that were heavier (MTA Cooperative Group, 1999).
Prior to the NIMH-funded PATS there were
less than a dozen small placebo-controlled trials of
psychostimulants in preschool children, and all utilized immediate-release methylphenidate (Kratochvil
et al. 2004). Doses in these studies did not exceed
0.6 mg/kg, a narrower range than the 0.3–1.0 mg/kg
used in older children (Kratochvil et al. 2004), and
were administered q.i.d. or b.i.d., rather than the t.i.d.
schedule often required for optimal effect. Efficacy of
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methylphenidate in the preschool age group varies
from older children (Connor, 2002), as does the adverse effect profile (Firestone et al. 1998). PATS, which
used a titration model similar to the MTA’s, included
165 children aged 3.5–5 yr initially randomized to
either placebo or immediate-release methylphenidate
(1.25 mg, 2.5 mg, 5 mg or 7.5 mg t.i.d.). Subjects received a week of treatment with each dose during the
double-blind cross-over titration phase. Twenty-two
percent of subjects were identified as best responding
to 7.5 mg t.i.d. The mean final best dose in PATS was
14.22¡8.1 mg/d, or 0.7¡0.4 mg/kg.d (Greenhill et al.
2006).
When PATS data were compared to MTA data, it
was noted that the younger children had lower optimal
doses, by weight, of immediate-release methylphenidate (0.7 mg/kg.d compared to 1.0 mg/kg.d). Pharmacokinetic data also demonstrated a slower clearance
of a single dose of methylphenidate in 4- and 5-yr-old
children compared to school-aged children (Wigal et al.
2007). Tolerability seems to have age-related variability, with younger children demonstrating more
emotional adverse events (e.g. crabbiness, irritability
and proneness to crying) than school-aged children.
Thus, slower titration, closer monitoring and smaller
doses of stimulants are advised when treating preschool children (Pliszka, 2007).
Adverse effects
All formulations of the stimulant medications have
similar adverse-event profiles (Greenhill et al. 2002).
Delayed sleep-onset, decreased appetite, weight loss,
headache, stomach upset and increased heart rate
and blood pressure are common. Emotional outbursts
and irritability have also been frequently reported in
younger children (Wigal et al. 2006).
Concerns with cardiovascular safety of ADHD
pharmacotherapies have led to specific recommendations for pre-treatment evaluation, treatment selection
and monitoring. Much scrutiny is given to the risks
present for children with structural cardiac abnormalities, but potentially medication-related changes in
heart rate and blood pressure are also observed in
healthy children with ADHD. In a study of 10 yr of
Florida Medicaid claims, stimulant use in patients
with ADHD was associated with 20 % more emergency-room visits, and 21 % more office visits for cardiac symptoms (Winterstein et al. 2007).
Gould et al. reported that the rate of sudden death in
paediatric patients taking a psychostimulant was the
same as that seen in the general population, with
11 sudden deaths reported between 1992 and 2005.
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However, in a matched case-control study, a significant association of stimulant use with sudden death
was seen when comparing data for 564 reports of
sudden death in 7- to 19-yr-olds with the deaths of 564
same-aged patients who died in motor vehicle accidents (odds ratio 7.4, 95 % confidence interval 1.4–74.9)
(Gould et al. 2009).
The AAP (Perrin et al. 2008) recommends that a
targeted cardiac history and physical examination be
part of the assessment of a child prior to initiating
ADHD treatment. Questions regarding a prior patient
history of heart disease, palpitations, syncope or seizures, or a family history of sudden death in children
or young adults, cardiomyopathy or long-QT syndrome should be asked. If these are present, an ECG
and/or referral to a cardiologist may be warranted
prior to initiating treatment. These cardiovascular
risks may become more of an issue in the treatment of
adults who may have concurrent hypertension and
cardiovascular disease.
Atomoxetine
Atomoxetine, which selectively blocks re-uptake at the
noradrenergic neuron, was the first non-stimulant
medication approved by the FDA for the treatment of
ADHD. Two large, DBPC efficacy studies demonstrated significant improvement in ADHD symptoms
with atomoxetine compared to placebo, with 64.1 %
and 58.7 % of atomoxetine subjects responding
(Spencer et al. 2002). More than a dozen DBPC trials
have provided evidence supporting the safety and efficacy of atomoxetine dosed both once and twice-daily
for the treatment of ADHD in children, adolescents,
and adults (Kelsey et al. 2004 ; Michelson et al. 2001,
2002, 2003 ; Spencer et al. 2002 ; Weiss et al. 2005).
The FDA-approved target therapeutic dose of
1.2 mg/kg.d was selected following a dose-finding
study which observed a graded dose-response to
atomoxetine 0.5 mg/kg.d and 1.2 mg/kg.d, but no
significant difference between 1.2 mg/kg.d and
1.8 mg/kg.d for reduction of core ADHD symptoms.
Improvements in psychosocial functioning, however,
were seen when the dose was increased to 1.8 mg/
kg.d without any significant difference in adverse
events (Michelson et al. 2001).
Atomoxetine is not approved for use in children
aged <6 yr. However, there has been one DBPC trial
(n=101), examining the use of atomoxetine in 5- and
6-yr-olds. Improvements were noted on parent and
teacher ADHD-IV ratings for children assigned to
atomoxetine compared to those on placebo (p<0.05).
Three subjects withdrew from the study due to

adverse events (atomoxetine=0, placebo=3). The
mean final daily dose of atomoxetine was 1.38 mg/
kg.d. Despite statistically significant improvements
in ADHD symptoms, and the fact that the parents received concomitant education on ADHD and behavioural interventions as a part of the study, the
children continued to have ADHD-IV (parent) scores
above the 86th percentile for age and gender at study
completion (Kratochvil et al. 2008 b).
Adverse effects
Common acute adverse effects of atomoxetine include
sedation, loss of appetite, nausea, vomiting, irritability, and headaches. In an analysis of the efficacy and
tolerability of atomoxetine in young vs. older children,
no significant differences were noted in the adverseevent profile or response to atomoxetine (Kratochvil
et al. 2008a).
Atomoxetine carries additional warnings for hepatotoxicity and suicidality risk. An analysis of
laboratory data from 7961 adult and paediatric
subjects in atomoxetine clinical trials revealed 41 instances of elevations in AST and ALT. There were
351 spontaneous reports of hepatic events in the first
4 yr atomoxetine was on the market. Of these, three
suggested atomoxetine as a probable cause, and 1/3
had a positive re-challenge. In all three cases, symptoms resolved following discontinuation of atomoxetine. These data resulted in recommendation that
atomoxetine be discontinued if jaundice or elevations
in hepatic enzymes are present (Bangs et al. 2008a).
A 2008 analysis of data from 14 studies of atomoxetine by Bangs and colleagues demonstrated that
suicide ideation was more common in subjects receiving atomoxetine (0.37 %, 5/1357 subjects) compared to those receiving placebo (0 %, 0/851 subjects).
To place the risk of suicidality in context, the number needed to harm (NNH) was 227, whereas the
number needed to treat (NNT) to achieve remission
of ADHD symptoms was five. No suicides occurred in any of the trials in the analysis (Bangs et al.
2008b).
Stimulant and atomoxetine comparator trials
Atomoxetine and osmotic release oral system (OROS)
methylphenidate
In a comparator trial in 516 children and adolescents
aged 6–16 with ADHD, subjects were randomized to
6 wk of treatment with either atomoxetine up to
1.8 mg/kg.d (n=222), OROS methylphenidate up to
54 mg/d (n=220) or placebo (n=74). Atomoxetine

Evidence-based ADHD pharmacotherapy
and OROS methylphenidate were both superior to
placebo, with 45 % (p<0.003) and 56 % (p<0.001) responding, respectively. Effect sizes were 0.6 for atomoxetine and 0.8 for OROS methylphenidate.
Decreased appetite was the only adverse event separating from placebo for both active treatments
(p<0.05). Subjects receiving OROS methylphenidate
reported experiencing insomnia, while those assigned
to atomoxetine had more frequent complaints of
somnolence. Weight loss and increased diastolic blood
pressure (p<0.05) were noted to be significant for both
drugs compared to placebo, and an increased pulse
rate was significant in the atomoxetine group compared to OROS methylphenidate and placebo
(p<0.05) (Newcorn et al. 2008).
For the stimulant-naive patients (n=191) participating in this trial, response rates to atomoxetine (57 %,
p=0.004) and methylphenidate (64 %, pf0.001) were
comparable (p=0.43), but those subjects with prior exposure to stimulants (n=301), had better responses to
methylphenidate (51 %, p=0.002) than to atomoxetine
(37 %, p=0.09) (p=0.03) (Newcorn et al. 2008). The effect size for atomoxetine was greater in stimulant-naive
patients (0.9), compared to patients previously treated
with stimulants (0.5), while the effect-sizes for OROS
methylphenidate in patients not previously treated
with a stimulant and with prior exposure were 1.0 and
0.8, respectively (Newcorn et al. 2008).
Subjects initially assigned to OROS methylphenidate were then switched to atomoxetine at the end of
the 6-wk acute treatment phase of the study. Forty-two
percent (29/69 subjects) who did not respond to atomoxetine in the second phase of the study had previously responded to OROS methylphenidate during
acute treatment, while 43 % of subjects who did not
respond acutely to OROS methylphenidate (30/70
subjects) went on to respond to atomoxetine. This may
indicate a differential response to treatment for some
patients (Newcorn et al. 2008).
Atomoxetine and mixed-amphetamine salts
In a 3-wk laboratory school comparison of atomoxetine and extended-release mixed amphetamine salts
in 6- to 12-yr-olds with either combined or hyperactive-impulsive type ADHD, improved attention and
academic performance were noted with both treatments. Mixed amphetamine salts-treated subjects had
greater improvements than those who received atomoxetine (p<0.001). The difference at endpoint was
statistically and clinically significant ; however, the
relatively short 3-wk duration of the study may not
have been sufficient to demonstrate the full effect of
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atomoxetine treatment. The mixed amphetamine salts
group reported experiencing insomnia, decreased
appetite, upper abdominal pain, anorexia and headache, while the most common adverse events reported
in the atomoxetine group were somnolence, appetite
decrease, upper abdominal pain, vomiting and headache. Vital sign changes were similar for both groups
and were not statistically significant (Wigal et al. 2005).
a2 agonists
The a2 adrenergic agents, clonidine (Catapres) and
immediate-release guanfacine (Tenex), have been used
relatively commonly over the past decade as secondline or adjunctive treatments in the USA. International
comparisons (Winterstein et al. 2008), however, show
very different co-medication patterns between the
USA and European countries where a2 adrenergic
agents are rarely used. Clonidine has been shown to
reduce ADHD symptoms in patients with comorbid
tics, aggression and conduct disorder. Immediaterelease clonidine is short-acting and requires multiple
divided doses throughout the day (Brown et al. 2005).
In the USA clonidine is also available as a transdermal
patch, allowing for once-weekly application. An extended-release formulation (KapvayTM) was approved
by the FDA in September 2010, for the treatment of
ADHD in children and adolescents aged 6–17 yr.
Kapvay received approval as both monotherapy and
in combination with a stimulant.
Guanfacine is a more selective a2-adrenergic agonist
with less sedation and a longer duration of action
(Biederman & Spencer, 2008). A small open-label
study of immediate-release guanfacine showed improvements in hyperactivity and inattention, with
transient sedation as the most common adverse event
(Hunt et al. 1995), and additional studies have demonstrated its utility and good tolerability in treating
ADHD with co-occurring tic disorders and Tourette’s
(Chappell et al. 1995 ; Scahill et al. 2001). An extendedrelease form of guanfacine was given FDA approval in
2009 as monotherapy for paediatric ADHD following
two controlled trials (study 1 : n=345, ages 6–17 yr ;
study 2 : n=324, ages 6–17 yr). Adverse events were
largely dose-dependent. Both studies had similar tolerability data, with the most common treatmentemergent adverse events being headache, somnolence,
fatigue, sedation, and upper abdominal pain. No
clinically significant vital sign or ECG changes were
seen (Biederman et al. 2008b ; Sallee et al. 2009b). Dosebased effect sizes ranged from 0.43 to 0.86, and response rates were 43 % for the 3-mg dose and 62 % for
the 4-mg dose.
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Guanfacine’s most common acute adverse effects
include somnolence, headache, fatigue, upper abdominal pain and sedation. Bradycardia was reported
in long-term studies (Biederman et al. 2008a ; Sallee
et al. 2009a)

decreases in ADHD symptoms, the MTA subjects as a
group still had relatively poorer ratings of behaviour,
academic and overall functioning compared to normal
controls at 6- and 8-yr follow-ups.
How long should treatment last?

What is the impact of ADHD pharmacotherapy?
The benefits of pharmacotherapy are most evident
in reduction of the core symptoms of ADHD. By reducing inattention, hyperactivity and impulsivity,
patients with ADHD are better able to perform academically and socially. Studies have demonstrated
that children treated with stimulants have improved
attention to school work, decreased disruptive
behaviours and decreased non-compliance. Shortterm data also shows improvements in academic performance and productivity (Barkley, 1998). Some
data suggest that children with ADHD treated
with psychostimulants demonstrate better academic
outcomes as evidenced by WIAT-II subtests and
high school grade point average (GPA) than children
with ADHD who were not treated. However, the
treated children did not do as well as non-ADHD
controls. It is unclear if pharmacotherapy alone translates to long-term academic success (Powers et al.
2008).
Social interactions between affected children and
their parents, teachers and peers are significantly improved with stimulant treatment. Treated children are
more compliant with commands and more appropriately responsive to interactions with others, with less
negative and off-task behaviour. As a result, adult redirections and supervision needs decrease, and praise
and positive attention to the child increase. ADHD
children treated with stimulants also appear to be
better accepted by peers, probably as a result of reduced negative and aggressive behaviour (Barkley,
1998). Health-related quality-of-life outcomes measured by the Child Health Questionnaire (CHQ) were
improved along with ADHD symptoms in children
treated with atomoxetine in a DBPC dosimetry study
in children and adolescents aged 8–18 yr (Michelson
et al. 2001).
Early treatment with methylphenidate does not
appear to increase risk for negative outcomes, and
may have beneficial long-term effects (Mannuzza et al.
2008). However, long-term data from the MTA study
notes that benefits of pharmacotherapy are sustainable
up to 2 yr for the majority of subjects followed,
but by the third year of follow-up, only about one
third of subjects demonstrated ongoing benefit with
medication treatment (Swanson et al. 2008). Despite

Epidemiological surveys of community samples indicate that 2–6 % of preschool children meet diagnostic
criteria for ADHD (Angold et al. 2000 ; Lavigne et al.
1996), with prevalence rates in school-aged children
conservatively estimated to be between 3 % and 7 %
(APA, 2000). As children grow into adolescence and
adulthood the prevalence of ADHD decreases, yet still
persists in significant numbers, estimated at approximately 3–4 % in adults (Fayyad et al. 2007). Even
though the presentation may vary from early childhood to adulthood, the impairment there is no less
significant (Kessler et al. 2006). A multitude of studies
have demonstrated a correlation between ADHD in
adults and global impairment in functioning, including : smoking and substance abuse, diminished rates
of college graduation, occupational/vocational difficulties, motor vehicle accidents, legal problems, unplanned pregnancies, and relationship problems
(Barkley, 2006).
In a 10-yr case-controlled follow-up study of 112
male adults with ADHD, potential protective factors
of stimulant treatment for ADHD were assessed.
Biederman et al. (2008 c, 2009) found no evidence that
stimulant treatment in childhood or adolescence either
increased or decreased the risk for development of
substance use disorders in young adulthood, but that
ADHD patients treated with stimulants were at significantly less risk of developing depressive and anxiety disorders, disruptive behaviour, and repeating a
grade in school than the ADHD patients who were not
treated. Daviss et al. also demonstrated a similar finding of ADHD pharmacotherapy reducing the risk of
later major depression (Daviss et al. 2008).
With the longitudinal course of ADHD documented, the AACAP Practice Parameter recommendations serve as a reminder to periodically
evaluate the need for ongoing treatment of ADHD
with pharmacotherapy. Follow-up clinic visits ensure
that medication remains effective, dosing is optimal,
and adverse events are minimized. The AACAP recommends that ADHD treatment be individualized,
and that the duration of treatment should continue as
long as impairing symptoms are present (Pliszka,
2007).
Considerable evidence demonstrating the efficacy
of psychostimulants in treating adults with ADHD
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(Asherson, 2005), led to FDA approval of both methylphenidate (extended-release methylphenidate and
d-methylphenidate) and amphetamine (extendedrelease mixed amphetamine salts). Atomoxetine has
also received FDA approval for adults with ADHD
based on two DBPC studies (Buitelaar et al. 2007).
Adverse effects
A specific concern with long-term pharmacotherapy
is impact on growth, so much so that the AACAP
Practice Parameter for ADHD treatment includes a
specific recommendation regarding regular height and
weight monitoring, including serial plotting of growth
parameters. The AACAP advises that a change in
height or weight crossing two percentile lines is
suggestive of abnormal growth and warrants a medication holiday, dose adjustment or change. Reductions
in growth must be balanced with benefits of treatment
(Pliszka, 2007).
Swanson et al. (2005) demonstrated that children
treated with stimulants grew more slowly and appeared to gain less weight than expected ; however,
they also theorized that, in general, children with
ADHD may have different growth trajectories than
their ‘normal ’ peers. Statistically significant delays in
height and weight were also seen with stimulant
treatment in a meta-analysis of 22 studies by Faraone
et al. (2008). The pooled data showed that the weight
deficits were more significant than the deficits seen in
height (p=0.002), although, both appeared to normalize over time (Faraone et al. 2008).
Based upon a qualitative meta-analysis, Faraone
et al. suggested that the effects on weight and height
may be dose-dependent. There was no apparent
difference, however, in the growth effects between
methylphenidate and amphetamine, and cessation of
treatment appeared to normalize growth (Faraone et al.
2008). This normalization of growth with breaks over
the summer or with drug discontinuation has been
demonstrated in additional studies (Gittelman et al.
1988 ; Kaffman et al. 1979 ; Klein & Mannuzza, 1988 ;
Safer et al. 1975) ; although analysis of data from the
MTA study (MTA Cooperative Group, 2004) showed
that while discontinuation of methylphenidate treatment did not reverse losses in expected height, it did
have a beneficial effect on weight gain.
Atomoxetine has also been clearly linked with
changes in height and weight trajectories, which for
the group appeared to dissipate over time, despite
continued treatment (Spencer et al. 2005, 2007). These
data appear to indicate that for most children growth
suppression, if present, will be transient and not
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clinically significant over time. Nonetheless, there is
clearly an effect of these medications on growth.
Therefore, while group averages over time may not be
overly concerning, close monitoring of individual
children taking ADHD medication is clearly indicated.
What is the management of treatment-resistant
cases?
The vast majority of patients with ADHD will respond
to one of the FDA-approved pharmacotherapies for
the treatment of ADHD. If a patient does not respond
adequately to appropriate trials (adequate duration
and optimal dose) of these agents, a re-assessment
of the diagnosis is warranted both to confirm the
diagnosis of ADHD and to re-examine for missed
co-occurring disorders (AACAP recommendation).
Co-occurrence of learning disorders, developmental
disorders and other psychiatric conditions can affect
response to treatment and/or complicate treatment
planning, and the addition of behavioural therapy to
a medication regimen may be required. Non-FDAapproved pharmacotherapies (e.g. bupropion or tricyclic antidepressants) may be tried if interventions
with a greater evidence base are either ineffective or
contraindicated. Finally, combination therapy with
FDA-approved agents and/or non-approved agents
might be clinically indicated. Use of medications not
approved for the treatment of ADHD, and treatment
with more than one medication simultaneously elevates potential risks, however, and these risks as well
as other treatment options must be discussed with the
patient and caregivers, and if employed monitored
closely (Pliszka, 2007).
Conclusion
ADHD is one of the best studied disorders in psychiatry. Reliable diagnosis at a young age is possible,
and recognition of ADHD as a potentially life-long
impairing disorder is increasing. As data emerge
which describe the physiological evidence behind the
historically ‘behavioural ’ diagnosis, acceptance of the
role of pharmacotherapy has increased for preschool
children through adults. Guidelines such as those
from the AACAP provide clear recommendations to
the practising clinician for diagnosing, treating and
monitoring patients with ADHD, in a manner which
maximizes effectiveness, tolerability, and ultimately,
functionality of the patient. As improvements are
made in the delivery systems and durations of effect of
the various psychostimulant agents, clinicians and
patients will still be faced with what to do for those
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who do not respond. Research is expanding into
non-stimulant agents, and the specific role these may
have. Further examination of a potential ‘differential
response ’, as suggested in the comparator trial of atomoxetine and OROS methylphenidate, may ultimately
better inform clinicians as to the selection of a specific
pharmacotherapy for a specific individual. In the interim, appropriate diagnosis, informed prescribing,
clinical monitoring and collaborative treatment planning, can all help to optimize outcomes in ADHD
management.
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